Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › skin melanoma

Skin melanoma

Part of Cancer

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for skin melanoma

32 trials tracked for skin melanoma: 2 in phase 3 or 4.

32Trials tracked
2Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 2 Phase 2 21 Phase 1 2 Other / NA 7
  1. Phase 3 SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer Completed
  2. Phase 3 S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma Completed
  3. Phase 2 Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma Completed
  4. Phase 2 Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma Completed
  5. Phase 2 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma Completed
  6. Phase 2 Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma Completed
Show 26 more trials
  1. Phase 2 Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma Completed
  2. Phase 2 A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). Completed
  3. Phase 2 Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma Completed
  4. Phase 2 Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Completed
  5. Phase 2 Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed
  6. Phase 2 Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma Completed
  7. Phase 2 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Completed
  8. Phase 2 Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery Completed
  9. Phase 2 PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma Completed
  10. Phase 2 Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma Completed
  11. Phase 2 Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma Completed
  12. Phase 2 Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Completed
  13. Phase 2 Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma Completed
  14. Phase 2 Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery Completed
  15. Phase 2 Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma Completed
  16. Phase 2 Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery Completed
  17. Phase 2 Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery Completed
  18. Phase 1 Vaccine Therapy in Treating Patients With Metastatic Melanoma Completed
  19. Phase 1 Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Completed
  20. N/A Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors Completed
  21. N/A Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo Completed
  22. N/A Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers Completed
  23. N/A AI-based Medical Device Validation for Early Melanoma Detection Completed
  24. N/A Skin Health Online for Melanoma: Better Risk Assessment Completed
  25. N/A Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma. Completed
  26. N/A Using MC1R Genotype to Impact Melanoma Risk Behavior Completed

Showing the 32 most-cited and recently-updated of 32 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Skin melanoma: what the trials found

New evidence includes the implementation of AI-based Computer-Aided Diagnosis (CAD) Software for skin lesion analysis 1.

Treatment with bevacizumab has been evaluated in multiple studies, including a trial reporting a tumor response rate of 23.8% to 33.3% and progression-free survival at 6 months ranging from 32.8% to 56.1% [14, 16].

Aldesleukin was evaluated in several trials; one study showed a significant increase in tumor-antigen-specific immunity in sentinel immunized nodes (SIN) by Elispot assay (p=0.004), while no significant difference was found in peripheral blood mononuclear cells (PBMC) [18, 21, 22].

Interleukin-2 treatment demonstrated a statistically significant improvement in 5-year relapse-free survival (47% vs 38%, p=0.02), though no significant difference was found in 5-year overall survival (56% vs 56%, p=0.49) 3.

The IC-Green KIT was evaluated in a Phase 3 trial 2.

Recent results — preliminary, needs further review

  • ANV419 was evaluated in a Phase 2 study 4.

For the clinician treating this condition

  • Aldesleukin shows significant evidence of inducing tumor-antigen-specific immunity in sentinel immunized nodes [18, 21, 22].
  • Interleukin-2 is associated with improved 5-year relapse-free survival but does not significantly impact 5-year overall survival 3.
  • Bevacizumab has demonstrated measurable tumor response rates and progression-free survival at 6 months in clinical trials [14, 16].

AI synthesis of 4 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review discusses ginsenosides for skin conditions including psoriasis and dermatitis with noted evidence gaps
Drug Pipeline Sys. Review
Narrative review discusses ginsenosides for skin conditions including psoriasis and dermatitis with noted evidence gaps Review of ginsenosides for skin conditions shows weak evidence and low absorption
This narrative review examines the use of ginsenosides for various skin conditions, including psoriasis, dermatitis, photoaging, chronic non…
A review of ginsenosides for skin issues like psoriasis and melanoma found the evidence is insufficient and absorption is low.
Frontiers Apr 24, 2026

Research across Cancer

Related studies from across the Cancer family.

Dual immune checkpoint inhibition provides durable intracranial progression-free survival in melanoma patients with brain metastases
Oncology Meta-analysis
Dual immune checkpoint inhibition provides durable intracranial progression-free survival in melanoma patients with brain metastases Dual immune therapy shows promise for melanoma brain metastases
This meta-analysis of 3,518 patients with cutaneous or mucosal melanoma brain metastases indicates that dual immune checkpoint inhibition pr…
Combining two immune therapies may offer more durable results for patients with melanoma that has spread to the brain.
Oct 28, 2026
miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types
Drug Pipeline Meta-analysis
miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types miR-155 Expression Linked to Treatment Resistance in Various Cancers
This systematic review of 19 studies across 8 cancer types indicates that miR-155 overexpression is associated with treatment resistance in …
Research suggests that high levels of a specific molecule, miR-155, may be linked to how well certain cancers respond to treatment.
Frontiers Oct 21, 2026
PD-1/PD-L1 inhibitors with SRS or FSRT achieve 87% one-year local control in brain metastases
Oncology Meta-analysis
PD-1/PD-L1 inhibitors with SRS or FSRT achieve 87% one-year local control in brain metastases Combining immunotherapy and radiation for brain metastases shows promise
This meta-analysis of 2587 patients with brain metastases evaluated the combination of PD-1/PD-L1 inhibitors with stereotactic radiosurgery …
A new analysis shows that combining specific immunotherapy drugs with radiation can help control brain tumors and manage side effects.
Oct 18, 2026
Genetic risk factors and a validated polygenic risk score identify melanoma risk loci
Genetics & Precision Medicine Meta-analysis
Genetic risk factors and a validated polygenic risk score identify melanoma risk loci Genetic Risk Factors Linked to Melanoma Development Identified
This meta-analysis of 69,871 cases and 1,616,233 controls identifies 156 independent signals at 116 risk loci for cutaneous melanoma. The st…
Researchers identified over 150 genetic signals linked to melanoma, helping to better understand how genetics influence skin cancer risk.
medRxiv Oct 16, 2026
CIC-Rearranged Intracranial Sarcoma: Local Control Achieved but Distant Spread Rapid Despite Multimodal Therapy
Oncology Sys. Review
CIC-Rearranged Intracranial Sarcoma: Local Control Achieved but Distant Spread Rapid Despite Multimodal Therapy Rare brain tumor appears in patient with history of melanoma
This is a single-patient case report of a 36-year-old woman with a prior history of melanoma who developed an intracranial sarcoma. Gross to…
A 36-year-old woman with a history of melanoma developed a rare type of brain tumor called an intracranial sarcoma.
Frontiers Oct 13, 2026
mRNA vaccines provide a clinically validated platform to induce durable anti-tumor immunity in solid tumors
Oncology Sys. Review
mRNA vaccines provide a clinically validated platform to induce durable anti-tumor immunity in solid tumors mRNA Vaccines Show Potential for Treating Several Solid Tumors
This systematic review evaluates mRNA vaccines for melanoma, pancreatic cancer, and non-small cell lung cancer. The authors conclude that mR…
mRNA technology is being used to create cancer vaccines that may help patients with melanoma, pancreatic, and lung cancers by building lasti…
Frontiers Oct 10, 2026
Artificial Intelligence Performance in Dermatoscopic Image Interpretation for Skin Cancer Diagnosis
Dermatology Meta-analysis
Artificial Intelligence Performance in Dermatoscopic Image Interpretation for Skin Cancer Diagnosis AI Shows High Performance in Detecting Skin Cancer Images
A meta-analysis of 208 articles evaluates how AI compares to expert dermatoscopy in identifying melanoma and other common skin malignancies.
Artificial intelligence may improve the accuracy of diagnosing skin cancers like melanoma when analyzing specialized skin images.
Oct 1, 2026
Approximately 40% to 55% of patients with advanced melanoma exhibit primary resistance to PD-1 monotherapy
Oncology Sys. Review
Approximately 40% to 55% of patients with advanced melanoma exhibit primary resistance to PD-1 monotherapy PD-1 Inhibitors Show Varying Resistance Rates in Advanced Melanoma
This systematic review examines resistance mechanisms to PD-1 and PD-L1 inhibitors in patients with advanced melanoma. It identifies primary…
New research identifies specific rates of initial and acquired resistance to PD-1 inhibitors in patients with advanced melanoma.
Frontiers Sep 27, 2026
MITF E318K variant associated with significantly increased melanoma risk and high nevus burden
Oncology Meta-analysis
MITF E318K variant associated with significantly increased melanoma risk and high nevus burden Specific gene variant linked to higher risk of multiple melanomas
This systematic review and meta-analysis of 8,606 melanoma patients and 17,953 controls identifies the MITF E318K variant as a moderate-pene…
A specific genetic variant called MITF E318K is linked to a significantly higher risk of developing multiple primary melanomas.
Sep 20, 2026
Melanoma Immunoediting Review Maps Elimination, Equilibrium, Escape and Drivers of Immunotherapy Resistance
Oncology Sys. Review
Melanoma Immunoediting Review Maps Elimination, Equilibrium, Escape and Drivers of Immunotherapy Resistance Immune System Changes Drive Melanoma Growth and Treatment Resistance
This systematic review synthesizes the tumor immunoediting framework in melanoma, describing three sequential phases (elimination, equilibri…
New research highlights how the immune system's failure to eliminate melanoma cells leads to tumor growth and resistance to current therapie…
Frontiers Sep 19, 2026
Medicinal plant extracts and phytochemicals show potential as multitargeted candidates for metastatic melanoma
Drug Pipeline Sys. Review
Medicinal plant extracts and phytochemicals show potential as multitargeted candidates for metastatic melanoma Plant extracts show promise for treating advanced melanoma skin cancer
This narrative review explores the potential of medicinal plant extracts and isolated phytochemicals as multitargeted therapeutic candidates…
Certain medicinal plants and their natural compounds may offer a new way to target multiple pathways in advanced melanoma.
Frontiers Sep 14, 2026
Self-administered ivermectin and fenbendazole in a patient with metastatic melanoma showed mixed radiographic and ctDNA responses
Oncology Guideline
Self-administered ivermectin and fenbendazole in a patient with metastatic melanoma showed mixed radiographic and ctDNA responses One man with melanoma tries antiparasitic drugs for his cancer
This case report describes a 74-year-old man with metastatic melanoma who self-administered ivermectin and fenbendazole. The patient experie…
A man with advanced melanoma saw a temporary drop in cancer markers after taking ivermectin and fenbendazole, but the results were mixed.
Frontiers Sep 14, 2026